{"id":"gsk576428","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in inflammatory cells, which suppresses the release of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce excessive inflammatory responses in autoimmune and inflammatory conditions. The drug's selectivity for PDE4 aims to provide anti-inflammatory effects while minimizing off-target effects associated with broader PDE inhibition.","oneSentence":"GSK576428 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels in immune cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:39.003Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory bowel disease"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT00320424","phase":"PHASE3","title":"Hip Fracture Study of GSK576428 (Fondaparinux Sodium)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-16","conditions":"Thromboembolism","enrollment":48},{"nctId":"NCT00320398","phase":"PHASE3","title":"Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-30","conditions":"Thrombosis, Venous","enrollment":114},{"nctId":"NCT00981409","phase":"PHASE3","title":"The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07","conditions":"Embolism, Pulmonary","enrollment":41},{"nctId":"NCT00911157","phase":"PHASE3","title":"The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06","conditions":"Thrombosis, Venous","enrollment":39},{"nctId":"NCT00333021","phase":"PHASE3","title":"Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"Venous Thromboembolism","enrollment":127}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fondaparinux sodium"],"phase":"phase_3","status":"active","brandName":"GSK576428","genericName":"GSK576428","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GSK576428 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels in immune cells. Used for Inflammatory bowel disease, Psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}